Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...

Biotech firms focused on gene therapies traded higher after Eli Lilly (NYSE:LLY) agreed to acquire Boston-based gene-editing ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also ...

Boston-based Verve Therapeutics is a Nasdaq-traded company focused on genetic medicines for cardiovascular disease.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of ...

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular diseaseLilly's established capabilities ...

Eli Lilly (NYSE:LLY) shares swooned on word the drug giant will acquire gene-editing startup Verve Therapeutics (NASDAQ:VERV) for up to $1.3 billion, the companies said on Tuesday. Lilly has struck ...

Shares of Verve Therapeutics ( VERV 76.56%) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. And for good reason. Eli Lilly ( LLY -0.90%) and Verve Therapeutics announced a "definitive ...

As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech ...

NEW YORK (AP) — U.S. stocks are nudging lower on Tuesday, and oil prices are rising again. It’s a modest return to form for ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to advance at a resilient ...